BR112017021589A2 - métodos para o tratamento de transtornos cardiovasculares - Google Patents

métodos para o tratamento de transtornos cardiovasculares

Info

Publication number
BR112017021589A2
BR112017021589A2 BR112017021589A BR112017021589A BR112017021589A2 BR 112017021589 A2 BR112017021589 A2 BR 112017021589A2 BR 112017021589 A BR112017021589 A BR 112017021589A BR 112017021589 A BR112017021589 A BR 112017021589A BR 112017021589 A2 BR112017021589 A2 BR 112017021589A2
Authority
BR
Brazil
Prior art keywords
cardiovascular disorders
treating cardiovascular
methods
solvate
formula
Prior art date
Application number
BR112017021589A
Other languages
English (en)
Other versions
BR112017021589B1 (pt
Inventor
Albert Eleutherius Van 't Klooster Gerben
Tom Bert Paul Wigerinck Piet
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1506228.4A external-priority patent/GB201506228D0/en
Priority claimed from GBGB1507109.5A external-priority patent/GB201507109D0/en
Priority claimed from GBGB1513344.0A external-priority patent/GB201513344D0/en
Priority claimed from GBGB1513991.8A external-priority patent/GB201513991D0/en
Priority claimed from GBGB1521542.9A external-priority patent/GB201521542D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112017021589A2 publication Critical patent/BR112017021589A2/pt
Publication of BR112017021589B1 publication Critical patent/BR112017021589B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção descreve compostos de acordo com a fórmula (i): ou um sal farmaceuticamente aceitável do mesmo ou um solvato ou sal de um solvato do mesmo, composições farmacêuticas que compreendem os mesmos, e métodos de tratamento usando os mesmos para uso em profilaxia e/ou tratamento de transtornos cardiovasculares e/ou dislipidemia por meio de administração do composto de acordo com a fórmula (i).
BR112017021589-6A 2015-04-13 2016-03-31 Uso de compostos que inibem jak1 para preparação de composições farmacêuticas e/ou medicamentos para tratamento de aterosclerose e/ou dislipidemia BR112017021589B1 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB1506228.4 2015-04-13
GBGB1506228.4A GB201506228D0 (en) 2015-04-13 2015-04-13 Methods For The Treatment Of Cardivascular Disorders
GB1507109.5 2015-04-27
GBGB1507109.5A GB201507109D0 (en) 2015-04-27 2015-04-27 Methods for the treatment of cardiovascular disorders
GBGB1513344.0A GB201513344D0 (en) 2015-07-29 2015-07-29 Methods for the treatment of Cardiovascular disorders
GB1513344.0 2015-07-29
GB1513991.8 2015-08-07
GBGB1513991.8A GB201513991D0 (en) 2015-08-07 2015-08-07 Methods for the treatment of cardiovascular disorders
GBGB1521542.9A GB201521542D0 (en) 2015-12-07 2015-12-07 Methods for the treatment of cardiovascular disorders
GB1521542.9 2015-12-07
PCT/EP2016/057103 WO2016165952A1 (en) 2015-04-13 2016-03-31 Methods for the treatment of cardiovascular disorders

Publications (2)

Publication Number Publication Date
BR112017021589A2 true BR112017021589A2 (pt) 2018-07-03
BR112017021589B1 BR112017021589B1 (pt) 2023-05-09

Family

ID=55640760

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021589-6A BR112017021589B1 (pt) 2015-04-13 2016-03-31 Uso de compostos que inibem jak1 para preparação de composições farmacêuticas e/ou medicamentos para tratamento de aterosclerose e/ou dislipidemia

Country Status (18)

Country Link
US (1) US10376520B2 (pt)
EP (1) EP3283114B1 (pt)
JP (1) JP6898249B2 (pt)
KR (1) KR20170134751A (pt)
CN (1) CN107438609B (pt)
AU (1) AU2016248727B2 (pt)
BR (1) BR112017021589B1 (pt)
CA (1) CA2982629C (pt)
EA (1) EA037911B1 (pt)
ES (1) ES2959612T3 (pt)
HK (1) HK1250624A1 (pt)
HR (1) HRP20231192T1 (pt)
HU (1) HUE063820T2 (pt)
MX (1) MX2017013103A (pt)
PL (1) PL3283114T3 (pt)
RS (1) RS64677B1 (pt)
SG (1) SG11201708198SA (pt)
WO (1) WO2016165952A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538103A1 (en) 2016-11-10 2019-09-18 Galapagos NV Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
PL2863950T3 (pl) 2012-06-22 2019-02-28 Galapagos Nv Aminotriazolopirydyna do zastosowania w leczeniu zapalenia i jej kompozycje farmaceutyczne
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20170141833A1 (en) * 2015-01-23 2017-05-18 Samsung Electronics Co., Ltd. Method and device for supporting data communication in wireless communication system

Also Published As

Publication number Publication date
US20180185377A1 (en) 2018-07-05
HRP20231192T1 (hr) 2024-02-16
RS64677B1 (sr) 2023-11-30
AU2016248727B2 (en) 2021-04-01
CA2982629C (en) 2023-09-05
KR20170134751A (ko) 2017-12-06
CN107438609A (zh) 2017-12-05
CN107438609B (zh) 2020-10-09
BR112017021589B1 (pt) 2023-05-09
CA2982629A1 (en) 2016-10-20
PL3283114T3 (pl) 2024-01-03
AU2016248727A1 (en) 2017-10-19
WO2016165952A1 (en) 2016-10-20
HUE063820T2 (hu) 2024-02-28
ES2959612T3 (es) 2024-02-27
EP3283114B1 (en) 2023-09-06
HK1250624A1 (zh) 2019-01-11
JP6898249B2 (ja) 2021-07-07
MX2017013103A (es) 2018-01-30
EA201792265A1 (ru) 2018-04-30
EP3283114C0 (en) 2023-09-06
EP3283114A1 (en) 2018-02-21
NZ735883A (en) 2021-11-26
US10376520B2 (en) 2019-08-13
EA037911B1 (ru) 2021-06-04
JP2018511618A (ja) 2018-04-26
SG11201708198SA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
BR112018070859A2 (pt) degradantes da proteína de bet
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112016005881A2 (pt) composto, composição farmacêutica e uso do composto
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2016, OBSERVADAS AS CONDICOES LEGAIS